

Bölüm 6

KANSER TEDAVİSİNDE İMMUNOTERAPİ

Özkan ALAN¹

GİRİŞ

Tümör immünolojisi son yıllarda kanser tedavisinde popüler araştırma konusu haline gelmiştir. İlk olarak 19.yy'da William Coley yumuşak doku sarkomu hastalarında ölü bakterilerin enjekte edilmesi sonucu gelişen immün reaksiyonun tümörde gerilemeye neden olduğu bildirmiştir (1). Bu tarihten itibaren immün sistem ile tümör gelişimi ve progresyonu arasındaki ilişkinin ortaya konması günümüzde tüm kanser türlerinde yeni tedavi seçeneklerinin geliştirilmesine yol açmıştır.

TÜMÖR İMMUNOLOJİSİ

Tümör hücrelerine karşı etkili ve spesifik bir sitotoksik immün tepki doğal ve adaptif immün sistemdeki çeşitli bağışıklık hücreleri arasında karmaşık ve hızla gelişen bir etkileşim gerektirir.

Tümöral İmmunitede Etkin Hücre Tipleri

CD8+ T lenfositleri ve CD4 + T lenfositleri tümöre karşı gelişen hücrel immün sistemde rol oynar. Literatürde sitotoksik T hücreleri (CD8+) ve yardımcı T hücreleri (CD4+) olarak adlandırılır. CD 4+ T lenfositlerinin T helper 1 ve 2 olmak üzere iki ana alt sınıfı vardır. FoxP3 + CD25 + CD4 + T düzenleyici (Treg) ve miyeloid türevli baskılayıcı hücreler (MDSC'ler) gibi hücre tipleri, sitotoksik T lenfosit aktivitesini büyük ölçüde inhibe eder.Doğal öldürücü (Natural killer) hücreler antijen sunumuna gerek olmadan tümör hücrelerine karşı sitotoksik etki gösterir. Makrofajlarda doğal hücrel immün sistemin üyesidir. Başlıca iki fenotipi vardır. Makrofaj 1 hücreleri interferon (IFN) gama salgılar ve fagositozdan

¹ Uzm. Dr. Özkan ALAN Tekirdağ Devlet Hastanesi Medikal Onkoloji Bölümü ozkan.alan@hotmail.com

Atezolizumab (Tecentriq)	PDL-1 inhibitörü	1-Metastatik küçük hücreli akciğer kanseri 2-Metastatik ürotelyal karsinom 3- Metastatik küçük hücreli dışı akciğer kanseri 4- Hormon ve her 2 negatif metastatik meme kanseri	1-Metastatik küçük hücreli ve küçük hücreli dışı akciğer kanseri
Avelumab (Bavencio)	PDL-1 inhibitörü	1-Metastatik merkel hücreli karsinom 2-Metastatik ürotelyal karsinom 3- Metastatik renal hücreli karsinom	- Türkiye'de onayı yok
Durvalumab (İmfinsi)	PDL-1 inhibitörü	1-Metastatik ürotelyal karsinom 2- Lokal ileri inoperal küçük hücreli akciğer kanserinde kemoradyoterapi sonrası idame tedavide	-Türkiye'de onayı yok

KAYNAKLAR

1. Coley WB, The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. *Am J Med Sci.* 1893;105:487.
2. Gras Navarro A, Björklund AT and Chekenya M (2015) Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. *Front. Immunol.* 6:202. doi: 10.3389/fimmu.2015.00202
3. Savage PA, Leventhal DS, Malchow S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. *Immunol Rev* 2014; 259:245.
4. Bailey SR, Nelson MH, Himes RA, et al. Th17 cells in cancer: the ultimate identity crisis. *Front Immunol* 2014; 5:276.
5. Laoui D, Van Overmeire E, De Baetselier P, et al. Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. *Front Immunol* 2014; 5:489.
6. Krieg C, Létourneau S, Pantaleo G, Boyman O Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. *Proc Natl Acad Sci U S A.* 2010 Jun;107(26):11906-11. Epub 2010 Jun 14
7. van der Merwe, P., Dushek, O. Mechanisms for T cell receptor triggering. *Nat Rev Immunol* 11, 47–55 (2011) doi:10.1038/nri2887
8. Wherry, E. T cell exhaustion. *Nat Immunol* 12, 492–499 (2011) doi:10.1038/ni.2035
9. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell* 2015; 160:48.
10. Amend SR, Pienta KJ. Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. *Oncotarget* 2015; 6:9669.

11. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 2014; 515:568.
12. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. *JAMA* 1994; 271:907.
13. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 1999; 17:2105.
14. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med* 2017; 377:1824.
15. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *N Engl J Med* 2016; 375:1845.
16. Motzer RJ, Hutson TE, Tomczak P, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med* 356, 115–124
17. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *J Clin Oncol* 2015; 33:1889.
18. A.M.M. Eggermont, V. Chiarion-Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *N Engl J Med*. 2016 November 10; 375(19): 1845–1855. doi:10.1056/NEJMoa1611299
19. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010; 363:711.
20. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011; 364:2517.
21. Antoni Ribas, Richard Kefford, Margaret A et al. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. *J Clin Oncol*. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7
22. Lebbé C, Meyer N, Mortier L, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the Phase IIIb/IV CheckMate 511 Trial. *J Clin Oncol*. 2019;37(11):867-875.
23. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. *J Clin Oncol* 2019; 37:537.
24. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. *J Clin Oncol*. 2016;34(13):1510-1517. doi: 10.1200/JCO.2015.64.0391
25. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. *J Clin Oncol* 2019; 37:537.
26. Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med* 2018; 379:2220.
27. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*. 2017;389(10066):255-265.
28. Schmid P, Adams S, Rugo HS, et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379(22):2108-2121. doi: 10.1056/NEJMoa1809615.
29. D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial. *JAMA Oncol*. 2018;4(9):e180077
30. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2019;380(12):1103-1115

31. Fabrice Barlesi, Johan Vansteenkiste, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200):an open-label, randomised, phase 3 study. *Lancet Oncology*. Volume 19, Issue 11, p1468-1479, November 01, 2018
32. Antonia SJ, Villegas A, Daniel D, et al; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC [published online September 25, 2018]. *N Engl J Med*. 2018
33. Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. *JAMA Oncol* 2017; 3:e172411.